Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | General Counsel, SVP Legal | December 18, 2019 | December 20, 2019 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | See Remarks | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date December 18, 2019 · Filed December 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2029-12-18 | Direct | 35,000 |
Reported balance
After 2019-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-18 · Grant · Acquired 35,000 · Balance 35,000 F1: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter.
Spyre Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,845 |
Ending reported balance
After 2026-10-01 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 28,933 · Balance 31,778 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. Row 2 · 2026-10-01 · Sale · Disposed 400 · Balance 31,378 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-10-01 · Sale · Disposed 16,605 · Balance 14,773 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-10-01 · Sale · Disposed 7,228 · Balance 7,545 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-10-01 · Sale · Disposed 2,100 · Balance 5,445 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2026-10-01 · Sale · Disposed 2,600 · Balance 2,845 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.50 · Expires 2033-09-01 | Direct | 482,478 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 28,933 · Balance 482,478 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F7: This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Provention Bio, Inc.
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $11.23 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-27 · Disposition to issuer · Disposed 139,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.39 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Disposition to issuer · Disposed 145,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.93 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-27 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.
F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,933 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · derivative · entry 7 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 482,478 Underlying: Common Stock · 28,933 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F7 · derivative.exercise_date: This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,600 | $93.46 | $242,996.00 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · nonDerivative · entry 6 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,845 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,100 | $92.70 | $194,670.00 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · nonDerivative · entry 5 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,445 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 7,228 | $91.35 | $660,277.80 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · nonDerivative · entry 4 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,545 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 16,605 | $90.35 | $1,500,261.75 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · nonDerivative · entry 3 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,773 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 400 | $89.24 | $35,696.00 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · nonDerivative · entry 2 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,378 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 28,933 | $14.50 | $419,528.50 |
DisclosureSEC source: 0001636282-26-000119 · wk-form4_1790991012.xml · nonDerivative · entry 1 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · derivative · entry 9 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 511,411 Underlying: Common Stock · 400 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F6 · derivative.exercise_date: This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 400 | $90.00 | $36,000.00 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 7 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,845 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 400 | $14.50 | $5,800.00 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 6 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,999 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · derivative · entry 8 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 511,811 Underlying: Common Stock · 27,999 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F6 · derivative.exercise_date: This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 400 | $89.38 | $35,752.00 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 5 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,845 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 6,206 | $88.17 | $547,183.02 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 4 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,245 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 16,548 | $87.20 | $1,442,985.60 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 3 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,451 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 4,845 | $86.40 | $418,608.00 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 2 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,999 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 27,999 | $14.50 | $405,985.50 |
DisclosureSEC source: 0001636282-26-000111 · wk-form4_1788485651.xml · nonDerivative · entry 1 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2 · balance_after: Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:25 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $30.61 | $0.00 |
DisclosureSEC source: 0001636282-26-000001 · wk-form4_1768357531.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 95,500 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001636282-25-000007 · wk-form4_1737149638.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,500 Underlying: Common Stock · 95,500 shares Expires 2035-01-15 F1 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 01:23 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $25.86 | $0.00 |
DisclosureSEC source: 0000950170-24-010896 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2034-02-01 F1 · derivative.exercise_date: This option represents a right to purchase 63,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 13,495,255 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000950170-23-046396 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,495,255 Underlying: Common Stock · 13,495,255 shares Expires 2033-09-01 F1 · derivative.exercise_date: This option represents the right to purchase 13,495,255 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 200,000 | Not disclosed Strike: $8.93 | Not disclosed |
DisclosureSEC source: 0001493152-23-013903 · ownership.xml · derivative · entry 4 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 145,000 | Not disclosed Strike: $4.39 | Not disclosed |
DisclosureSEC source: 0001493152-23-013903 · ownership.xml · derivative · entry 3 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 139,500 | Not disclosed Strike: $6.80 | Not disclosed |
DisclosureSEC source: 0001493152-23-013903 · ownership.xml · derivative · entry 2 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 139,500 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 300,000 | Not disclosed Strike: $11.23 | Not disclosed |
DisclosureSEC source: 0001493152-23-013903 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:11 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001493152-23-001209 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.0001 · 200,000 shares Expires 2033-01-10 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027). Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:28 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001493152-22-033640 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock, par value $0.0001 · 90,000 shares Expires 2030-08-03 F1 · shares: As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 90,000 of the 180,000 performance option shares on November 22, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 90,000 option shares. F2 · price: The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F3 · balance_after: Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares which vested August 3, 2021 plus 60,000 vested performance option shares which vested March 22, 2022 plus the 90,000 vested performance option shares referred to in footnote (1). Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 18:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001493152-22-007705 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock, par value $0.0001 · 60,000 shares Expires 2030-08-03 F1 · shares: As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 60,000 of the 180,000 performance option shares on March 22, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 60,000 option shares. F2 · price: The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F3 · balance_after: Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares which vested August 3, 2021 plus the 60,000 vested performance options shares referred to in footnote (1). Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:22 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001493152-22-001759 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, par value $0.0001 · 145,000 shares Expires 2032-01-18 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 18, 2023) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 18, 2026). Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 16:07 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001493152-21-018719 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2030-08-03 F1 · shares: As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 30,000 of the 180,000 performance option shares on August 3, 2021 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 30,000 option shares. F2 · price: The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F3 · balance_after: Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares referred to in footnote (1). Excludes 150,000 of the previously reported 300,000 option shares referred to in footnote (1) that are performance option shares that remain subject to vesting upon completion of certain performance milestones. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:41 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 139,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001493152-21-011581 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,500 Underlying: Common Stock, par value $0.0001 · 139,500 shares Expires 2031-05-12 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024. Read SEC document |
| August 03, 2020 Filed Aug 3, 2020 17:35 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001493152-20-014505 · ownership.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock, par value $0.0001 · 300,000 shares Expires 2030-08-03 F1 · derivative.exercise_date: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. 120,000 option shares vest in four equal annual installments commencing on August 3, 2021; the remaining 180,000 option shares vest upon completion of certain performance milestones. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 20:03 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001104659-19-075209 · a4.xml · derivative · entry 1 King-Jones Heidy · CIK 0001794898 · General Counsel, SVP Legal 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-12-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.